Details
Stereochemistry | RACEMIC |
Molecular Formula | C36H41N3O6 |
Molecular Weight | 611.7286 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C(c2cccc(c2)N(=O)=O)C(=C(C)N1)C(=O)OC(C)(C)CN(C)CCC(c3ccccc3)c4ccccc4)C(=O)OC
InChI
InChIKey=ZDXUKAKRHYTAKV-UHFFFAOYSA-N
InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
Molecular Formula | C36H41N3O6 |
Molecular Weight | 611.7286 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.drugs.com/history/lercanidipine.html | https://www.ncbi.nlm.nih.gov/pubmed/27794423
Curator's Comment:: description was created based on several sources, including
https://www.drugs.com/history/lercanidipine.html | https://www.ncbi.nlm.nih.gov/pubmed/27794423
Lercanidipine is antihypertensive drugs which acts by blocking L-type calcium channels, allowing relaxation and opening of blood vessels. Lercanidipine exists as a racemate, with anti-hypertensive activity residing primarily in S-enantiomer. NDA for lercanidipine was submitted to FDA in 2002 by Forest Laboratories, but FDA refused to approve the drug, and lercanidipine is not marketed in USA. Lercanidipine is also investigated in preclinical models of epilepsy and ischemic stroke.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26673531
Curator's Comment:: Active in a preclinical models of epilepsy on mice
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16173926 |
2.2 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZANIDIP Approved UseLercanidipine is indicated for the treatment of mild to moderate essential hypertension |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue. | 2005 Sep |
|
Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. | 2006 Apr |
|
Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. | 2006 Jan |
|
Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. | 2006 Jan |
|
Fixed-dose combination lercanidipine/enalapril. | 2007 |
|
Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of stroke in rats. | 2017 Feb |
Sample Use Guides
The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response. In preclinical models lercanidipine is administered intraperitoneally.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16173926
Lercanidipine demonstrated vasodilation effect in isolated vessel ring obtained from human arteria mammaria preparation (EC50 approx. 1 nM). Isolated vessel rings were precontracted by 0.3 mol/L prostaglandin F2.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 22:56:57 UTC 2021
by
admin
on
Fri Jun 25 22:56:57 UTC 2021
|
Record UNII |
V7XTJ4R0BH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C09DB08
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
||
|
WHO-ATC |
C08CA13
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
||
|
WHO-ATC |
C09BB02
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
||
|
WHO-VATC |
QC09BB02
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
||
|
WHO-VATC |
QC08CA13
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C060343
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
V7XTJ4R0BH
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
LERCANIDIPINE
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
DB00528
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
4157
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
6971
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
65866
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
C81687
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
CHEMBL250270
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
100427-26-7
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
100427-26-7
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
M6770
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | Merck Index | ||
|
SUB08437MIG
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | |||
|
135056
Created by
admin on Fri Jun 25 22:56:57 UTC 2021 , Edited by admin on Fri Jun 25 22:56:57 UTC 2021
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |